Shorr L D, Sirinek K R, Page C P, Levine B A
J Surg Res. 1984 Apr;36(4):384-8. doi: 10.1016/0022-4804(84)90115-x.
Reports from other investigators have shown the ability of pretreatment with either parenteral (glucose) or enteral (bolus Vivonex HN) nutrition to protect against stress ulcer formation, suggesting that the mechanism of protection may be substrate availability. However, these prior animal studies have used inordinately high amounts of Vivonex HN (equal to 1050 ml/hr in a human). This study compared cytoprotection afforded by pretreatment with a continuous infusion of Vivonex HN at a more clinically applicable level to that of both parenteral (ip) and enteral (po) glucose to test the above hypothesis. One hundred eight rats were infused (0.1 ml/min) for 30 min with: po water, ip water, po 25% glucose, ip 25% glucose, or po Vivonex HN. This was followed by 2 hr of cold-restraint stress. Serum glucose was determined. Poststress, animals were sacrificed, stomachs inspected, and mean ulcer index was calculated. Only oral 25% glucose offered significant gastric cytoprotection. Serum glucose was highest in both glucose groups.
(1) Vivonex HN pretreatment failed to cytoprotect in this model, (2) gastric cytoprotection by oral but not by parenteral glucose in the presence of similar serum glucose levels suggests that luminal factors, in addition to substrate availability, are necessary for this protection to occur.
其他研究人员的报告表明,肠外(葡萄糖)或肠内(推注Vivonex HN)营养预处理具有预防应激性溃疡形成的能力,这表明保护机制可能是底物可用性。然而,这些先前的动物研究使用了极高剂量的Vivonex HN(相当于人类1050毫升/小时)。本研究将以更临床适用水平持续输注Vivonex HN预处理提供的细胞保护作用与肠外(腹腔注射)和肠内(口服)葡萄糖的细胞保护作用进行比较,以验证上述假设。108只大鼠分别以0.1毫升/分钟的速度输注30分钟:口服水、腹腔注射水、口服25%葡萄糖、腹腔注射25%葡萄糖或口服Vivonex HN。随后进行2小时的冷束缚应激。测定血清葡萄糖。应激后,处死动物,检查胃部,并计算平均溃疡指数。只有口服25%葡萄糖提供了显著的胃细胞保护作用。两个葡萄糖组的血清葡萄糖水平最高。
(1)在该模型中,Vivonex HN预处理未能提供细胞保护作用;(2)在血清葡萄糖水平相似的情况下,口服而非肠外葡萄糖提供胃细胞保护作用,这表明除了底物可用性外,管腔因素对于这种保护的发生也是必要的。